A couple of the slides GK presented at the EGM point to the differences between the trials - the comparisons indicate the patients in the Lupin trial were 'no less advanced' in terms of their cancer vs the WARMTH study.
The 19.7 MOs has the chance to improve as further data is collected up until October this year.
GK also hinted at the potential to go up to 2400mg dosage in future trials .
He also indicated that he is "very comfortable" with the IP situation as the increasing data set allows for claims which a far more novel & inventive versus the initial patents lodged.![]()
- Forums
- ASX - By Stock
- Ann: New Independent Trial Data Supports Potential of Veyonda
NOX
noxopharm limited
Add to My Watchlist
5.88%
!
4.8¢

A couple of the slides GK presented at the EGM point to the...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
4.8¢ |
Change
-0.003(5.88%) |
Mkt cap ! $14.02M |
Open | High | Low | Value | Volume |
5.0¢ | 5.0¢ | 4.8¢ | $24.18K | 499.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1020 | 4.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.0¢ | 140633 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1020 | 0.048 |
2 | 114034 | 0.047 |
1 | 50000 | 0.046 |
3 | 30444 | 0.045 |
1 | 70000 | 0.044 |
Price($) | Vol. | No. |
---|---|---|
0.050 | 140633 | 2 |
0.051 | 107266 | 2 |
0.052 | 78600 | 1 |
0.055 | 60000 | 1 |
0.056 | 20000 | 1 |
Last trade - 15.41pm 08/07/2025 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |